Marvin Maslow - Manhattan Scients Chairman

MHTX Stock  USD 0.0008  0.0001  11.11%   

Chairman

Mr. Marvin Maslow is Chairman of the Board of the Company. He served as the CEO of Manhattan Scientifics from January 1998 until November 2007. On March 13, 2015, Mr. Maslow was appointed as a director of the Company. From June 1990 through September 1996, Mr. Maslow served as chief executive officer of Projectavision, Inc., a company he cofounded to develop and market video projection technology. For more than 20 years, Mr. Maslow was President of Normandie Capital Corporationration, a private investment and consulting company. Mr. Maslow is credited with the starting up and financing of more than 20 enterprises during his career. Mr. Maslow received an A.A.S. degree from the Rochester Institute of Technology in 1957 and an honorable discharge from the U.S. Army Signal Corporationration in 1963 since 2015.
Age 85
Tenure 9 years
Phone212 541 2405
Webhttps://www.mhtx.com
Maslow serves as a paid consultant to the Company, attends board meetings and serves as a special advisor to the Board of Directors. He also serves as a Manager of the Company’s Senior Scientifics LLC subsidiary.

Manhattan Scients Management Efficiency

The company has return on total asset (ROA) of (0.1724) % which means that it has lost $0.1724 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5111) %, meaning that it created substantial loss on money invested by shareholders. Manhattan Scients' management efficiency ratios could be used to measure how well Manhattan Scients manages its routine affairs as well as how well it operates its assets and liabilities.
Manhattan Scients currently holds 143 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Manhattan Scients has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Manhattan Scients until it has trouble settling it off, either with new capital or with free cash flow. So, Manhattan Scients' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Manhattan Scients sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Manhattan to invest in growth at high rates of return. When we think about Manhattan Scients' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CHAIRMAN Age

Eric WeisblumSilo Pharma
54
Mark EmalfarbDyadic International
68
MD MPHMineralys Therapeutics, Common
47
Manhattan Scientifics, Inc., a technology incubator, engages in the development and commercialization of life-enhancing technologies in the United States. Manhattan Scientifics, Inc. was founded in 1992 and is based in New York, New York. Manhattan Scients operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 1 people. Manhattan Scients [MHTX] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Manhattan Scients Leadership Team

Elected by the shareholders, the Manhattan Scients' board of directors comprises two types of representatives: Manhattan Scients inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Manhattan. The board's role is to monitor Manhattan Scients' management team and ensure that shareholders' interests are well served. Manhattan Scients' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Manhattan Scients' outside directors are responsible for providing unbiased perspectives on the board's policies.
Leonard Friedman, Secretary and Director
Emmanuel Tsoupanarias, Chairman, CEO and President and Principal Accounting Officer
Marvin Maslow, Founder, Director and Chairman of Tamarack Storage Devices Inc
Robert Proulx, Pres Imagion

Manhattan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Manhattan Scients a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Manhattan Pink Sheet Analysis

When running Manhattan Scients' price analysis, check to measure Manhattan Scients' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Manhattan Scients is operating at the current time. Most of Manhattan Scients' value examination focuses on studying past and present price action to predict the probability of Manhattan Scients' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Manhattan Scients' price. Additionally, you may evaluate how the addition of Manhattan Scients to your portfolios can decrease your overall portfolio volatility.